Cargando…
Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920783/ https://www.ncbi.nlm.nih.gov/pubmed/35370047 http://dx.doi.org/10.1016/j.ejca.2022.02.032 |
| _version_ | 1784669197428588544 |
|---|---|
| author | Patelli, Giorgio Pani, Arianna Amatu, Alessio Scaglione, Francesco Sartore-Bianchi, Andrea |
| author_facet | Patelli, Giorgio Pani, Arianna Amatu, Alessio Scaglione, Francesco Sartore-Bianchi, Andrea |
| author_sort | Patelli, Giorgio |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8920783 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89207832022-03-15 Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients Patelli, Giorgio Pani, Arianna Amatu, Alessio Scaglione, Francesco Sartore-Bianchi, Andrea Eur J Cancer Letter to the Editor Elsevier Ltd. 2022-05 2022-03-15 /pmc/articles/PMC8920783/ /pubmed/35370047 http://dx.doi.org/10.1016/j.ejca.2022.02.032 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Patelli, Giorgio Pani, Arianna Amatu, Alessio Scaglione, Francesco Sartore-Bianchi, Andrea Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients |
| title | Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients |
| title_full | Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients |
| title_fullStr | Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients |
| title_full_unstemmed | Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients |
| title_short | Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients |
| title_sort | seroconversion after sars-cov-2 mrna booster vaccine in cancer patients |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920783/ https://www.ncbi.nlm.nih.gov/pubmed/35370047 http://dx.doi.org/10.1016/j.ejca.2022.02.032 |
| work_keys_str_mv | AT patelligiorgio seroconversionaftersarscov2mrnaboostervaccineincancerpatients AT paniarianna seroconversionaftersarscov2mrnaboostervaccineincancerpatients AT amatualessio seroconversionaftersarscov2mrnaboostervaccineincancerpatients AT scaglionefrancesco seroconversionaftersarscov2mrnaboostervaccineincancerpatients AT sartorebianchiandrea seroconversionaftersarscov2mrnaboostervaccineincancerpatients |